Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Terns Pharmaceuticals Inc (TERN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: TERN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.83
1 Year Target Price $15.83
| 5 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.65% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 679.96M USD | Price to earnings Ratio - | 1Y Target Price 15.83 |
Price to earnings Ratio - | 1Y Target Price 15.83 | ||
Volume (30-day avg) 9 | Beta -0.04 | 52 Weeks Range 1.86 - 9.03 | Updated Date 10/25/2025 |
52 Weeks Range 1.86 - 9.03 | Updated Date 10/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.03 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.97% | Return on Equity (TTM) -35.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 388401715 | Price to Sales(TTM) 302.64 |
Enterprise Value 388401715 | Price to Sales(TTM) 302.64 | ||
Enterprise Value to Revenue 337.47 | Enterprise Value to EBITDA -5.8 | Shares Outstanding 87511048 | Shares Floating 52507504 |
Shares Outstanding 87511048 | Shares Floating 52507504 | ||
Percent Insiders 0.3 | Percent Institutions 104.28 |
Upturn AI SWOT
Terns Pharmaceuticals Inc
Company Overview
History and Background
Terns Pharmaceuticals, Inc. is a global biopharmaceutical company founded in 2017 focused on developing and commercializing innovative therapies to treat liver diseases and cancer. They primarily focus on non-alcoholic steatohepatitis (NASH) and oncology.
Core Business Areas
- NASH Program: Development of small-molecule therapeutics for NASH, including TERN-501 (THR-beta agonist), TERN-601 (GLP-1R agonist), and combination therapies.
- Oncology Program: Development of small-molecule therapeutics for oncology, including TERN-701 (allosteric BTK inhibitor).
Leadership and Structure
Terns Pharmaceuticals is led by a team of experienced pharmaceutical executives and scientists. The structure involves research and development, clinical operations, and commercial strategy teams. Wenbin Jiang is the current CEO.
Top Products and Market Share
Key Offerings
- TERN-501 (THR-beta agonist): An oral THR-u03b2 agonist in Phase 2 clinical trials for NASH. Market share is currently 0 as it is still in development. Competitors include Madrigal Pharmaceuticals (resmetirom) and Viking Therapeutics (VK2809).
- TERN-601 (GLP-1R agonist): An oral GLP-1R agonist in Phase 1 clinical trials for NASH. Market share is currently 0 as it is still in development. Competitors include Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide).
- TERN-701 (allosteric BTK inhibitor): An allosteric BTK inhibitor in Phase 1 clinical trials for oncology indications. Market share is currently 0 as it is still in development. Competitors include Eli Lilly (pirtobrutinib) and AstraZeneca (acalabrutinib).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and innovative, driven by the need for new and improved therapies. NASH and oncology are areas with high unmet needs and significant market potential.
Positioning
Terns Pharmaceuticals is positioned as a clinical-stage company focused on developing novel therapies for liver diseases and cancer. Its competitive advantage lies in its pipeline of differentiated small-molecule therapeutics.
Total Addressable Market (TAM)
The global NASH market is projected to reach tens of billions of dollars by the late 2020s. The oncology market is significantly larger. Terns is positioned to capture a share of these markets if its clinical programs are successful.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting NASH and oncology
- Experienced leadership team
- Strong preclinical and clinical data for lead programs
- Strategic partnerships and collaborations
Weaknesses
- Clinical-stage company with no approved products
- High risk of clinical trial failures
- Dependence on external funding
- Relatively small company compared to competitors
Opportunities
- Positive clinical trial results driving market value
- Potential for partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Acquisition by a larger company
Threats
- Clinical trial failures or delays
- Regulatory hurdles and approval delays
- Competition from other companies developing similar therapies
- Changes in the regulatory landscape
- Economic downturn impacting funding availability
Competitors and Market Share
Key Competitors
- Madrigal Pharmaceuticals (MDGL)
- Viking Therapeutics (VKTX)
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
Competitive Landscape
Terns Pharmaceuticals faces intense competition from established pharmaceutical companies and other biotechs developing therapies for NASH and oncology. Its success depends on demonstrating superior efficacy and safety profiles for its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily measured by pipeline advancement and clinical trial progress.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approvals for its lead programs, particularly TERN-501 and TERN-601. Analyst estimates vary depending on trial outcomes.
Recent Initiatives: Recent initiatives include advancing TERN-501 and TERN-601 into Phase 2 trials, expanding the pipeline through partnerships and collaborations, and securing additional funding to support clinical development.
Summary
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on NASH and oncology. Their pipeline of novel drug candidates holds promise, but faces significant clinical and regulatory risks. Success hinges on positive trial outcomes and securing partnerships to support development. The company should keep an eye on cash burn and competitor advancements.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor. Market share data for unapproved therapies are projections.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Terns Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2021-02-05 | CEO & Director Ms. Amy L. Burroughs M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://www.ternspharma.com |
Full time employees 59 | Website https://www.ternspharma.com | ||
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.